Lexicon Pharmaceuticals (NASDAQ:LXRX) Rating Reiterated by Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research report sent to investors on Tuesday, Benzinga reports.

Separately, StockNews.com raised shares of Lexicon Pharmaceuticals to a sell rating in a report on Monday, April 15th.

Lexicon Pharmaceuticals Price Performance

Shares of LXRX opened at $1.54 on Tuesday. The company has a quick ratio of 5.58, a current ratio of 5.60 and a debt-to-equity ratio of 1.07. Lexicon Pharmaceuticals has a 1 year low of $0.92 and a 1 year high of $3.79. The company has a 50 day simple moving average of $2.24 and a two-hundred day simple moving average of $1.72.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings data on Monday, March 11th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.03. Lexicon Pharmaceuticals had a negative net margin of 14,573.20% and a negative return on equity of 138.54%. The business had revenue of $0.70 million during the quarter, compared to analyst estimates of $0.68 million. Sell-side analysts anticipate that Lexicon Pharmaceuticals will post -0.71 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Cantor Fitzgerald L. P. bought a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at approximately $25,000. TIAA Trust National Association bought a new position in shares of Lexicon Pharmaceuticals during the 3rd quarter valued at approximately $29,000. Principal Securities Inc. bought a new position in shares of Lexicon Pharmaceuticals during the 4th quarter valued at approximately $33,000. Commonwealth Equity Services LLC boosted its position in shares of Lexicon Pharmaceuticals by 160.9% during the 3rd quarter. Commonwealth Equity Services LLC now owns 39,569 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 24,400 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Lexicon Pharmaceuticals by 350.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 28,329 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 22,043 shares during the last quarter. 74.70% of the stock is currently owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.